Has Sandra Parker received payments from drug or device companies?

Yes. Drug and device makers reported $5,362 in general payments to Sandra Parker across 173 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sandra Parker did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sandra Parker come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sandra Parker

Psychiatry · Mobile, ALNPI 1982606976

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 173 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Alkermes, Inc. at 42.6% of the total. 2025 is the largest year on record at $1,457, 3.2 times the $459 reported in 2019.

$5,362in general payments, 2019–2025

Across 173 payments — averaging $31.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Alkermes, Inc.$2K
Corium, LLC$607
Ironshore Pharmaceuticals Inc.$533
Otsuka America Pharmaceutical, Inc.$382
Johnson & Johnson$325
AbbVie$217
plus $1K from 14 others

What the payments were for

Food & beverage$5,33599%
Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Alkermes, Inc.	54	$2,283
Corium, LLC	23	$607
Ironshore Pharmaceuticals Inc.	5	$533
Otsuka America Pharmaceutical, Inc.	21	$382
Johnson & Johnson	14	$325
AbbVie	11	$217
Teva Pharmaceuticals USA, Inc.	8	$201
Neurocrine Biosciences, Inc.	7	$184
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	7	$143
E.r. Squibb & Sons, L.L.C.	4	$83
Takeda Pharmaceuticals U.S.A., Inc.	4	$68
Vanda Pharmaceuticals Inc.	2	$62
Indivior Inc.	2	$56
Axsome Therapeutics, Inc.	2	$53
Novo Nordisk	2	$44
Supernus Pharmaceuticals, Inc.	2	$38
GSK	2	$35
Hologic Sales And Service, LLC	1	$17
Lundbeck LLC	1	$16
Neos Therapeutics, LP	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LYBALVI$2,288
ARISTADA$1,448
Jornay PM 20mg capsules (Bottle of 100)$389
ARISTADA INITIO$362
JORNAY PM$130
Azstarys$122

How this compares

$5,362 in reported general payments places this provider in the 85th percentile of 400 psychiatry providers in Alabama.

See all psychiatry providers in Alabama →

Other psychiatry in Mobile

Mark HaygoodMobile$348K
Bradley SadlerMobile$124K
Michael MarshallMobile$59K
Mary Cohen ColsonMobile$10K
Lucas BooneMobile$10K
Bradley BrooksMobile$6K
Armand SchachterBirmingham$758K
Stephen HughesBirmingham$683K
Leesha Ellis CoxBirmingham$653K
Godehard OepenBirmingham$516K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →